NASDAQ:PODD

Insulet Stock Forecast, Price & News

$273.53
+1.02 (+0.37 %)
(As of 07/29/2021 03:22 PM ET)
Add
Compare
Today's Range
$272.46
$275.23
50-Day Range
$252.78
$286.77
52-Week Range
$192.98
$306.46
Volume4,497 shs
Average Volume483,306 shs
Market Capitalization$18.13 billion
P/E Ratio2,104.08
Dividend YieldN/A
Beta0.68
30 days | 90 days | 365 days | Advanced Chart
Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.


Insulet logo

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

920th out of 2,214 stocks

Surgical & Medical Instruments Industry

92nd out of 185 stocks

Analyst Opinion: 2.3Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

What stocks does MarketBeat like better than Insulet?

Wall Street analysts have given Insulet a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Insulet wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Insulet?

Insulet saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 1,850,000 shares, a drop of 28.3% from the May 31st total of 2,580,000 shares. Based on an average daily volume of 544,500 shares, the short-interest ratio is presently 3.4 days.
View Insulet's Short Interest
.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Insulet
.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Monday, February, 22nd. The medical instruments supplier reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.22. The medical instruments supplier earned $246.10 million during the quarter, compared to the consensus estimate of $232.89 million. Insulet had a net margin of 0.93% and a trailing twelve-month return on equity of 1.52%. Insulet's revenue was up 17.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.08 earnings per share.
View Insulet's earnings history
.

How has Insulet's stock been impacted by Coronavirus (COVID-19)?

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 59.8% and is now trading at $274.99.
View which stocks have been most impacted by COVID-19
.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its second quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $248.93 million-$257.98 million, compared to the consensus revenue estimate of $261.09 million.

What price target have analysts set for PODD?

14 Wall Street analysts have issued twelve-month price objectives for Insulet's stock. Their forecasts range from $230.00 to $325.00. On average, they expect Insulet's share price to reach $274.38 in the next twelve months. This suggests that the stock has a possible downside of 0.2%.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 47, Pay $1.8M)
  • Mr. Wayde D. McMillan, Exec. VP,CFO & Treasurer (Age 51, Pay $969.46k)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 61, Pay $1.05M)
  • Mr. Dan Manea, Sr. VP & Chief HR Officer (Age 54, Pay $841.64k)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 50, Pay $918.47k)
  • Ms. Lauren Budden, VP, Chief Accounting Officer & Controller
  • Ms. Deborah R. Gordon CPA, VP of Investor Relations
  • Mr. Michael Spears, Sr. VP of Quality and Regulatory Affairs & Compliance (Age 56)
  • Mr. John Wodick Kapples, Sr. VP, Sec. & Gen. Counsel (Age 61)
  • Angela Geryak Wiczek, Sr. Director of Corp. Communications

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.19%), State of Alaska Department of Revenue (0.03%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Scout Investments Inc.. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, John A Fallon, Sally Crawford, and Shacey Petrovic.
View insider buying and selling activity for Insulet
or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd.
View insider buying and selling activity for Insulet
or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $274.99.

How much money does Insulet make?

Insulet has a market capitalization of $18.22 billion and generates $904.40 million in revenue each year. The medical instruments supplier earns $6.80 million in net income (profit) each year or $0.10 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 1,900 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

Where are Insulet's headquarters?

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.